Characteristics of the VTE patients, relatives, and controls
| Characteristic . | VTE patients (n = 100) . | Relatives (n = 100) . | Controls (n = 100) . |
|---|---|---|---|
| Age, y | 53.1 ± 5.9 | 52.4 ± 5.8 | 51.9 ± 6.1 |
| Male sex, % | 52 | 49 | 50 |
| BMI, kg/m2 | 27.5 (25.2-29.6) | 26.8 (25.0-29.5) | 26.9 (24.9-29.1) |
| Current smokers, % | 23 | 27 | 26 |
| Hypertension, % | 30 | 29 | 28 |
| Medications | |||
| Aspirin, percentage | 18 | 15 | 12 |
| Statins, percentage | 20 | 21 | 16 |
| β-blockers, percentage | 21 | 24 | 22 |
| ACEI, percentage | 30 | 28 | 24 |
| Laboratory parameters | |||
| TC, mmol/L | 5.24 (3.84-6.12) | 5.31 (4.12-6.15) | 5.23 (3.95-6.19) |
| LDL-C, mmol/L | 2.98 ± 0.74 | 3.11 ± 0.78 | 3.08 ± 0.81 |
| HDL-C, mmol/L | 1.40 ± 0.37 | 1.38 ± 0.32 | 1.41 ± 0.42 |
| TG, mmol/L | 1.29 ± 0.61 | 1.38 ± 0.59 | 1.32 ± 0.62 |
| Glucose, mmol/L | 4.94 ± 0.67 | 5.12 ± 0.64 | 4.98 ± 0.71 |
| Creatinine, μmol/L | 68 (54-90) | 67 (52-91) | 64 (49-88) |
| Fibrinogen, g/L | 3.28 ± 0.98 | 3.0 ± 0.96 | 2.48 ± 1.09 |
| CRP, mg/L | 2.09 ± 1.60* | 1.37 ± 0.64 | 1.77 ± 2.03 |
| D-dimer, mg/dL | 195.2 ± 81.0*† | 127.1 ± 46.9 | 118.4 ± 39.3 |
| tPA, ng/mL | 9.50 ± 3.27*† | 10.30 ± 2.98 | 6.19 ± 2.22 |
| PAI-1, ng/mL | 13.64 ± 3.53*† | 10.11 ± 2.68 | 9.67 ± 2.62 |
| F1.2, nmol/L | 0.78 ± 0.20 | 0.74 ± 0.15 | 0.76 ± 0.17 |
| tHcy, μmol/L | 13.6 ± 3.4 | 13.3 ± 2.9 | 12.1 ± 4.2 |
| Characteristic . | VTE patients (n = 100) . | Relatives (n = 100) . | Controls (n = 100) . |
|---|---|---|---|
| Age, y | 53.1 ± 5.9 | 52.4 ± 5.8 | 51.9 ± 6.1 |
| Male sex, % | 52 | 49 | 50 |
| BMI, kg/m2 | 27.5 (25.2-29.6) | 26.8 (25.0-29.5) | 26.9 (24.9-29.1) |
| Current smokers, % | 23 | 27 | 26 |
| Hypertension, % | 30 | 29 | 28 |
| Medications | |||
| Aspirin, percentage | 18 | 15 | 12 |
| Statins, percentage | 20 | 21 | 16 |
| β-blockers, percentage | 21 | 24 | 22 |
| ACEI, percentage | 30 | 28 | 24 |
| Laboratory parameters | |||
| TC, mmol/L | 5.24 (3.84-6.12) | 5.31 (4.12-6.15) | 5.23 (3.95-6.19) |
| LDL-C, mmol/L | 2.98 ± 0.74 | 3.11 ± 0.78 | 3.08 ± 0.81 |
| HDL-C, mmol/L | 1.40 ± 0.37 | 1.38 ± 0.32 | 1.41 ± 0.42 |
| TG, mmol/L | 1.29 ± 0.61 | 1.38 ± 0.59 | 1.32 ± 0.62 |
| Glucose, mmol/L | 4.94 ± 0.67 | 5.12 ± 0.64 | 4.98 ± 0.71 |
| Creatinine, μmol/L | 68 (54-90) | 67 (52-91) | 64 (49-88) |
| Fibrinogen, g/L | 3.28 ± 0.98 | 3.0 ± 0.96 | 2.48 ± 1.09 |
| CRP, mg/L | 2.09 ± 1.60* | 1.37 ± 0.64 | 1.77 ± 2.03 |
| D-dimer, mg/dL | 195.2 ± 81.0*† | 127.1 ± 46.9 | 118.4 ± 39.3 |
| tPA, ng/mL | 9.50 ± 3.27*† | 10.30 ± 2.98 | 6.19 ± 2.22 |
| PAI-1, ng/mL | 13.64 ± 3.53*† | 10.11 ± 2.68 | 9.67 ± 2.62 |
| F1.2, nmol/L | 0.78 ± 0.20 | 0.74 ± 0.15 | 0.76 ± 0.17 |
| tHcy, μmol/L | 13.6 ± 3.4 | 13.3 ± 2.9 | 12.1 ± 4.2 |
Values are given as mean ± SD, median (interquartile range), or percentage.
VTE indicates venous thromboembolism; BMI, body mass index; ACEI, angiotensin-converting enzyme inhibitor; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglycerides; CRP, C-reactive protein; tPA, tissue-type plasminogen activator; PAI-1, plasminogen activator inhibitor-1; F1.2, prothrombin 1.2 fragments; and tHcy, total homocysteine.
P ≤ .001 vs controls.
P < .01 vs relatives.